# A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors

> **NCT05886075** · EARLY_PHASE1 · UNKNOWN · sponsor: **Shanghai Yunying Medical Technology** · enrollment: 24 (estimated)

## Conditions studied

- Lung Cancer
- Bronchial Cancer
- Non Small Cell Lung Cancer
- Small Cell Lung Cancer
- Sarcoma
- Colorectal Cancer
- Gastric Cancer
- Liver Cancer
- Breast Cancer
- Pancreatic Cancer
- Head and Neck Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** Recombinant oncolytic herpes simplex virus type 1 (R130)

## Key facts

- **NCT ID:** NCT05886075
- **Lead sponsor:** Shanghai Yunying Medical Technology
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-30
- **Primary completion:** 2025-03
- **Final completion:** 2025-03
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05886075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05886075, "A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT05886075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*